Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.
The company's financial arm could pay $27 billion in dividends.
Apple's China Troubles; MSG's Lin-sanity; Avon Gets Dinged; Energy Conversion Convulsion; Yahoo! Channels Charlie.
Watch for a bank ratings cut to damper 2012 share gains of the largest U.S. banks.
Senior columnist Adam Feuerstein explains why Vivus and Chelsea Therapeutics are the next big things in biotech.
Gilead's GS-7977 fails to cure hard-to-treat hepatitis C patients, showing the wonder drug has flaws.
U.S. stocks were mixed Friday as investors digested greater confidence about a Greek bailout and varied national inflation reads.
Apple had close to $100 billion in cash on its books at the end of the first quarter. Do investors have a legal right to it?
These are proven gainers with a measure of safety.
Philip van Doorn
In contrast to Bank of America's recent downgrade parade, Sterne Agee analyst Todd Hagerman on Friday raised his earnings estimate and price target for Wells Fargo, saying investors could see "an upside earnings surprise in 2012."